RCS - OptiBiotix Health - ProBiotix Health - Appointment of CEO

OptiBiotix HealthAnnouncement

20/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220620:nRST3405Pa&default-theme=true

RNS Number : 3405P  OptiBiotix Health PLC  20 June 2022

20 June 2022

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

ProBiotix Health - Appointment of Chief Executive Officer

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skin care, notes
the announcement (14 June 2022) by ProBiotix Health plc (AQSE: PBX)
("ProBiotix Health"), that Steen Andersen ("Steen") has been appointed as
Chief Executive Officer ("CEO"), and that Steen will join the company after
completing his notice period with his current employer. The Company has a 44
per cent. shareholding in ProBiotix Health.

 

This is part of a long-planned strategy by OptiBiotix and its portfolio
companies (the "Group") to appoint experienced industry commercial leaders to
each part of the business allowing the Group CEO to focus on identifying,
developing and acquiring the new technologies or companies that will provide
the Group with a pipeline of products and applications to deliver future
growth and market value. This structure gives shareholders exposure to
multiple opportunities within the emerging microbiome space and affords the
potential to deliver additional value through separate public listing of the
businesses and dividend return as achieved with the listing of ProBiotix
Health earlier in the year.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "The appointment of Steen as CEO
of ProBiotix Health will help accelerate the growth and recognition of the
business into its next phase of evolution.  Having established international
sales and brand awareness of its award winning LP(LDL)® probiotic as an
ingredient, ProBiotix Health is now investing in building a presence in the
dairy industry, extending the range of applications for LP(LDL)® into other
areas of health, and increasing access to the USA and Asian markets."

 

For further information, please contact:

 

 OptiBiotix Health plc                                                         www.optibiotix.com (http://www.optibiotix.com)
 Stephen O'Hara, Chief Executive                     Contact via Walbrook below

 finnCap (Broker)                                                              Tel: 020 7220 0500
 Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
 Abigail Wayne (Corporate Broking)

 Walbrook PR Ltd           Tel: 020 7933 8780 or optibiotix@walbrookpr.com
                           (mailto:optibiotix@walbrookpr.com)
 Anna Dunphy                                                                   Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the
human microbiome - the collective genome of the microbes in the body - to
prevent and manage human disease.

 

The aim of OptiBiotix is to discover and develop microbial strains, compounds
and formulations, which modulate the human microbiome and can be used as food
ingredients and supplements or active compounds for the prevention and
management of human metabolic diseases, examples of which include obesity,
cholesterol and lipid distribution and diabetes.

 

OptiBiotix has established a pipeline of microbiome modulators that can impact
on lipid and cholesterol management, energy harvest and appetite suppression.
The development pipeline is fuelled by its proprietary OptiScreen® and
OptiBiotic® platform technologies designed to identify metabolic pathways and
compounds that impact on human physiology and bring potential health benefits.

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFISREIDLIF